ArticleBlood neoplasia2025
Erratum: Uemura Y, Yamamoto M, Ishimura M, et al. JAK1/2 inhibitor ruxolitinib for the treatment of systemic chronic active Epstein-Barr virus disease: a phase 2 study.
PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.